Here’s Why Novartis (NVS) is a Strong Value Stock

NVS

Novartis Reports Updated Positive Data From Phase III SMA Program

NVS

Novartis bolsters late-stage cardiovascular pipeline with agreement to acquire Anthos Therapeutics for USD 925 million upfront

NVS

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024

NVS

AI, vaccine distrust, & the future of healthcare: Novartis CEO

Can science prevail against this more turbulent backdrop of the Trump administration? Yahoo Finance executive editor Brian Sozzi talks at...

NVS

Why Novartis (NVS) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why...

NVS

Novartis’ Gene Therapy Meets Primary Endpoint in SMA Study

NVS' phase III study on experimental gene therapy candidate Intrathecal onasemnogene abeparvovec (OAV101IT) meets its primary goal.

NVS

Here’s Why Novartis (NVS) is a Strong Growth Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why...

NVS

Novartis intrathecal onasemnogene abeparvovec Phase III study meets primary endpoint in children and young adults with SMA

Ad hoc announcement pursuant to Art. 53 LR The Phase III STEER study met its primary endpoint showing an increase...

This website automatically aggregates content from various other websites. The copyright of content and images belongs to those websites and their respective companies. We are not responsible for the content published here. Please ensure that all information is for reference only and not investment advice. However, we will strive to strictly control content that provides no value or brings negativity to the community.

No Result

View All Result